Find a Tender · Contract
ANMI PSMA kit VEAT notice
A public procurement published by The Royal Marsden NHS Foundation Trust via Find a Tender.
- —
- Award value
- —
- Tender value
- 1
- Suppliers
- 1
- Awards
- 1
- Notices
- Contract
- Stage
Overview
.The Royal Marsden Hospital requires purchase of ANMI PSMA Setrile 360 VIALS and ANMI Elution Tools Gen A to treat prostate cancer. ANMI PSMA Setrile 360 Vials and ANMI Elution Tools Gen A is the only viable kit for imaging of prostate cancer, disease progression or staging of cancer in UK. There is no licensed product in the UK at the moment, XIEL is the only official UK Distributor of the ANMI HBEDCC-11 PSMA Kit and follows the Regulated Import Pathway approved by the MHRA for this product.
Key details
- Source
- Find a Tender
- Lifecycle stage
- Contract
- Status
- complete
- CPV classification
- 33100000 — Medical equipments
- Currency
- GBP
- Total award value
- —
- Tender value
- —
- First published
- 16 May 2022
- Last updated
- 16 May 2022
Awards
1 award recorded on this procurement.
| Supplier | Companies House | Awarded | Status | Value |
|---|---|---|---|---|
| Xiel Limited | 11875702 | — | active | — |
Notice timeline
Every published notice in this procurement's lifecycle.
All suppliers
Frameworks & programmes
More from The Royal Marsden NHS Foundation Trust
FAQs about this procurement
Who is the buyer for "ANMI PSMA kit VEAT notice"?
ANMI PSMA kit VEAT notice is a UK public-sector procurement published by The Royal Marsden NHS Foundation Trust via Find a Tender.
Has "ANMI PSMA kit VEAT notice" been awarded?
Yes — 1 award is recorded. The current lifecycle stage is "Contract".
Which suppliers are involved in "ANMI PSMA kit VEAT notice"?
1 supplier is linked: Xiel Limited.
When was "ANMI PSMA kit VEAT notice" published?
It was first published on 16 May 2022 and last updated on 16 May 2022, across 1 notice.
Track procurements like this one
Enable monitors the entire UK public-contract pipeline — get alerts on buyers, suppliers and frameworks that matter to you.
Get in touch with Enable